15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Pasithea Therapeutics Corp, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $3.00 to $3.00, so the covering firms are broadly aligned. The average target of $3.00 sits 433% above the current $0.56. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-0.46 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Pasithea Therapeutics Corp.
As of Aug, 1 of 1 firms rate KTTA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KTTA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.25 – $-0.25 · 1 analysts · -72% YoY
Next period, 1 analysts expect Pasithea Therapeutics Corp to earn $-0.25 a share (range $-0.25 – $-0.25), versus $-0.89 a year earlier. Full-year consensus is $-0.76, growing to $-0.46 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Pasithea Therapeutics Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KTTA.
#1
SN
Sara Nik
HC Wainwright & Co.
Buy
$3.00+432.9% to target
Coverage
—
+ Follow
KTTA stock forecast FAQ
What is KTTA's average 12-month price target?+
The 1 analysts with a live target average $3.00 for Pasithea Therapeutics Corp over the next 12 months, ranging from a $3.00 high to a $3.00 low.
Is KTTA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover KTTA?+
1 analysts have an active rating on Pasithea Therapeutics Corp, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering KTTA?+
Among analysts who currently cover KTTA, Sara Nik of HC Wainwright & Co. has the strongest overall Quantellect track record. Their current call is Buy with a $3.00 target.
What is Pasithea Therapeutics Corp's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.25 – $-0.25) across 1 analysts. Full-year EPS is projected at $-0.76, rising to $-0.46 the following year.
How much revenue is Pasithea Therapeutics Corp expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading KTTA lately?+
As of Aug, 1 of 1 firms rate KTTA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KTTA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
